-
公开(公告)号:US20240350672A1
公开(公告)日:2024-10-24
申请号:US18617239
申请日:2024-03-26
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor: Tongyao LIU , Ekta Seth CHHABRA , Siyuan TAN
IPC: A61K48/00 , A61K38/00 , A61P7/04 , C07K14/755 , C12N15/85
CPC classification number: A61K48/0058 , A61P7/04 , C07K14/755 , C12N15/85 , A61K38/00
Abstract: The present disclosure provides codon optimized Factor VIII sequences, vectors, and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides.
-
公开(公告)号:US20220106383A1
公开(公告)日:2022-04-07
申请号:US17479705
申请日:2021-09-20
Applicant: Bioverativ Therapeutics Inc.
Inventor: Ekta Seth CHHABRA , John KULMAN , Tongyao LIU
IPC: C07K14/755 , A61K38/37
Abstract: The present invention provides a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker. The invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, wherein the chain comprising the VWF protein and the chain comprising the FVIII protein are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.
-
公开(公告)号:US20220275057A1
公开(公告)日:2022-09-01
申请号:US17519719
申请日:2021-11-05
Applicant: Bioverativ Therapeutics Inc.
Inventor: Ekta Seth CHHABRA , Tongyao LIU , Robert T. PETERS , John KULMAN
IPC: C07K14/755 , C07K16/00
Abstract: The present invention provides a chimeric protein comprising a first polypeptide which comprises a FVIII protein and a first Ig constant region or a portion thereof and a second polypeptide which comprises a VWF protein comprising the D′ domain and D3 domain of VWF, a XTEN sequence having less than 288 amino acids in length, and a second Ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.
-
公开(公告)号:US20190169267A1
公开(公告)日:2019-06-06
申请号:US16154310
申请日:2018-10-08
Applicant: Bioverativ Therapeutics Inc.
Inventor: Ekta Seth CHHABRA , Tongyao LIU , Pei-yun CHANG , Robert T. PETERS , John KULMAN
Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
-
公开(公告)号:US20230011438A1
公开(公告)日:2023-01-12
申请号:US17826932
申请日:2022-05-27
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor: Ekta Seth CHHABRA , Tongyao LIU , Robert T. PETERS , Haiyan JIANG
IPC: C07K14/755 , A61K47/62 , C07K16/00
Abstract: The present invention provides a VWF fragment comprising the D′ domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
-
公开(公告)号:US20210238259A1
公开(公告)日:2021-08-05
申请号:US16478747
申请日:2018-01-31
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor: Arjan VAN DER FLIER , Zhiqian LIU , David R. LIGHT , Ekta Seth CHHABRA , Tongyao LIU , Robert T. PETERS , John KULMAN , Ayman ISMAIL
IPC: C07K14/745 , C12N9/64
Abstract: The present disclosure provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present disclosure further discloses methods of making and using the FIX fusion proteins.
-
公开(公告)号:US20220056108A1
公开(公告)日:2022-02-24
申请号:US17358142
申请日:2021-06-25
Applicant: Bioverativ Therapeutics Inc.
Inventor: Ekta Seth CHHABRA , Tongyao LIU , Pei-yun CHANG , Robert T. PETERS , John KULMAN , Haiyan JIANG
Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.
-
公开(公告)号:US20210032616A1
公开(公告)日:2021-02-04
申请号:US16920970
申请日:2020-07-06
Applicant: Bioverativ Therapeutics Inc.
Inventor: Zhiqian LIU , Arjan VAN DER FLIER , David R. LIGHT , Ekta Seth CHHABRA , Tongyao LIU , Robert T. PETERS , John KULMAN , Ayman ISMAIL
Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.
-
公开(公告)号:US20240083975A1
公开(公告)日:2024-03-14
申请号:US18358601
申请日:2023-07-25
Applicant: Bioverativ Therapeutics Inc.
Inventor: Ekta Seth CHHABRA , John KULMAN , Tongyao LIU
IPC: C07K14/755 , A61K38/37
CPC classification number: C07K14/755 , A61K38/37 , A61K38/00
Abstract: The present invention provides a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker. The invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, wherein the chain comprising the VWF protein and the chain comprising the FVIII protein are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.
-
公开(公告)号:US20180355341A1
公开(公告)日:2018-12-13
申请号:US15750119
申请日:2016-08-03
Applicant: Bioverativ Therapeutics Inc.
Inventor: Zhiqian LIU , Ajan VAN DER FLIER , David R. LIGHT , Ekta Seth CHHABRA , Tongyao LIU , Robert T. PETERS , John KULMAN , Ayman ISMAIL
CPC classification number: C12N9/644 , A61K9/0019 , A61K38/00 , A61P7/04 , C07K14/00 , C07K2319/00 , C07K2319/30 , C12Y304/21022
Abstract: The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.
-
-
-
-
-
-
-
-
-